Is DNA or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -215.41% -56.08% -26.06% Biohaven N/A -866.46% -137.99%

Ginkgo Bioworks (DNA) Competitors

$10.36 -0.04 (-0.34%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$10.35 -0.02 (-0.14%)

As of 07/2/2026 07:53 PM Eastern

Compare

DNA vs. TWST, TRVI, MBX, SLS, and BHVN

Should you buy Ginkgo Bioworks stock or one of its competitors? MarketBeat compares Ginkgo Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ginkgo Bioworks include Twist Bioscience (TWST), Trevi Therapeutics (TRVI), MBX Biosciences (MBX), SELLAS Life Sciences Group (SLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Twist Bioscience has a net margin of -19.85% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -26.73% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Twist Bioscience	-19.85%	-26.73%	-19.15%

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A
Twist Bioscience	$409.48M	15.09	-$77.67M	-$1.33	N/A

In the previous week, Twist Bioscience had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 4 mentions for Twist Bioscience and 0 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.11 beat Ginkgo Bioworks' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Twist Bioscience	Positive

Ginkgo Bioworks presently has a consensus target price of $8.50, indicating a potential downside of 17.99%. Twist Bioscience has a consensus target price of $79.30, indicating a potential downside of 20.09%. Given Ginkgo Bioworks' higher possible upside, research analysts plainly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market.

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Trevi Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Trevi Therapeutics' return on equity of -24.53% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, Trevi Therapeutics' average media sentiment score of 0.00 equaled Ginkgo Bioworks'average media sentiment score.

Company	Overall Sentiment
Trevi Therapeutics	Neutral
Ginkgo Bioworks	Neutral

Trevi Therapeutics currently has a consensus target price of $22.67, suggesting a potential upside of 26.42%. Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential downside of 17.99%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Trevi Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A

Summary

Trevi Therapeutics beats Ginkgo Bioworks on 11 of the 14 factors compared between the two stocks.

How does Ginkgo Bioworks compare to MBX Biosciences?

Ginkgo Bioworks (NYSE:DNA) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

MBX Biosciences has lower revenue, but higher earnings than Ginkgo Bioworks. MBX Biosciences is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MBX Biosciences has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. MBX Biosciences' return on equity of -24.52% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
MBX Biosciences	N/A	-24.52%	-23.59%

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential downside of 17.99%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 4.19%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, MBX Biosciences had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for MBX Biosciences and 0 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.00 equaled MBX Biosciences'average media sentiment score.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
MBX Biosciences	Neutral

Summary

MBX Biosciences beats Ginkgo Bioworks on 11 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SELLAS Life Sciences Group currently has a consensus price target of $10.00, suggesting a potential downside of 33.24%. Ginkgo Bioworks has a consensus price target of $8.50, suggesting a potential downside of 17.99%. Given Ginkgo Bioworks' higher possible upside, analysts plainly believe Ginkgo Bioworks is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

SELLAS Life Sciences Group has higher earnings, but lower revenue than Ginkgo Bioworks. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. SELLAS Life Sciences Group's return on equity of -47.12% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, SELLAS Life Sciences Group had 10 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 0 mentions for Ginkgo Bioworks. SELLAS Life Sciences Group's average media sentiment score of 0.60 beat Ginkgo Bioworks' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Overall Sentiment
SELLAS Life Sciences Group	Positive
Ginkgo Bioworks	Neutral

SELLAS Life Sciences Group has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Summary

SELLAS Life Sciences Group beats Ginkgo Bioworks on 8 of the 14 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Biohaven?

Ginkgo Bioworks (NYSE:DNA) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Biohaven has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Biohaven	N/A	-866.46%	-137.99%

In the previous week, Biohaven had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Biohaven and 0 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.00 beat Biohaven's score of -0.25 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Biohaven	Neutral

Ginkgo Bioworks has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.98	-$312.76M	-$5.36	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential downside of 17.99%. Biohaven has a consensus price target of $21.63, suggesting a potential upside of 35.75%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Summary

Ginkgo Bioworks and Biohaven tied by winning 8 of the 16 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$679.37M	$3.78B	$7.16B	$23.53B
Dividend Yield	N/A	2.16%	2.66%	3.98%
P/E Ratio	-1.93	21.61	28.02	31.55
Price / Sales	3.98	340.19	540.37	21.06
Price / Cash	N/A	147.12	49.26	25.36
Price / Book	1.19	8.66	10.96	4.81
Net Income	-$312.76M	$23.81M	$3.57B	$1.07B
7 Day Performance	1.67%	3.39%	2.12%	0.56%
1 Month Performance	26.94%	10.81%	5.25%	4.54%
1 Year Performance	-18.10%	62.61%	33.29%	18.23%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	0.387 of 5 stars	$10.37 -0.3%	$8.50 -18.0%	-18.1%	$679.37M	$170.15M	N/A	640
TWST Twist Bioscience	1.53 of 5 stars	$98.36 -1.5%	$79.30 -19.4%	+160.4%	$6.22B	$376.57M	N/A	990	Positive News Gap Up
TRVI Trevi Therapeutics	2.1899 of 5 stars	$18.63 +2.6%	$22.90 +22.9%	+204.1%	$2.58B	N/A	N/A	20
MBX MBX Biosciences	0.8283 of 5 stars	$53.85 +2.9%	$60.22 +11.8%	N/A	$2.49B	N/A	N/A	N/A	News Coverage Gap Down
SLS SELLAS Life Sciences Group	0.3171 of 5 stars	$15.45 +24.7%	$10.00 -35.3%	+588.7%	$2.44B	N/A	N/A	10	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, TRVI, MBX, SLS, and BHVN

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Trevi Therapeutics?

Summary

How does Ginkgo Bioworks compare to MBX Biosciences?

Summary

How does Ginkgo Bioworks compare to SELLAS Life Sciences Group?

Summary

How does Ginkgo Bioworks compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, TRVI, MBX, SLS, and BHVN

How does Ginkgo Bioworks compare to Twist Bioscience?

Is DNA or TWST more profitable?

Do insiders and institutionals have more ownership in DNA or TWST?

Which has better valuation and earnings, DNA or TWST?

Does the media prefer DNA or TWST?

Do analysts rate DNA or TWST?

Which has more volatility & risk, DNA or TWST?

Summary

How does Ginkgo Bioworks compare to Trevi Therapeutics?

Do insiders & institutionals believe in TRVI or DNA?

Which has more volatility and risk, TRVI or DNA?

Is TRVI or DNA more profitable?

Does the media prefer TRVI or DNA?

Do analysts rate TRVI or DNA?

Which has higher valuation and earnings, TRVI or DNA?

Summary

How does Ginkgo Bioworks compare to MBX Biosciences?

Which has preferable earnings and valuation, DNA or MBX?

Which has more volatility and risk, DNA or MBX?

Do insiders and institutionals hold more shares of DNA or MBX?

Is DNA or MBX more profitable?

Do analysts prefer DNA or MBX?

Does the media prefer DNA or MBX?

Summary

How does Ginkgo Bioworks compare to SELLAS Life Sciences Group?

Do insiders & institutionals hold more shares of SLS or DNA?

Do analysts prefer SLS or DNA?

Which has higher earnings and valuation, SLS or DNA?

Is SLS or DNA more profitable?

Does the media refer more to SLS or DNA?

Which has more risk & volatility, SLS or DNA?

Summary

How does Ginkgo Bioworks compare to Biohaven?

Is DNA or BHVN more profitable?

Does the media refer more to DNA or BHVN?

Which has stronger valuation & earnings, DNA or BHVN?

Do institutionals & insiders hold more shares of DNA or BHVN?

Do analysts prefer DNA or BHVN?

Which has more volatility and risk, DNA or BHVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools